• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Time to Shock the System: Moving Beyond the Current Paradigm for Primary Prevention Implantable Cardioverter-Defibrillator Use.

作者信息

Merchant Faisal M, Levy Wayne C, Kramer Daniel B

机构信息

Section of Cardiac Electrophysiology Emory University School of Medicine Atlanta GA.

Cardiology Division University of Washington Seattle WA.

出版信息

J Am Heart Assoc. 2020 Mar 3;9(5):e015139. doi: 10.1161/JAHA.119.015139. Epub 2020 Feb 24.

DOI:10.1161/JAHA.119.015139
PMID:32089058
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7335546/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c905/7335546/760cc4427276/JAH3-9-e015139-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c905/7335546/f749b49927b9/JAH3-9-e015139-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c905/7335546/6c205ac147c6/JAH3-9-e015139-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c905/7335546/49383962570e/JAH3-9-e015139-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c905/7335546/760cc4427276/JAH3-9-e015139-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c905/7335546/f749b49927b9/JAH3-9-e015139-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c905/7335546/6c205ac147c6/JAH3-9-e015139-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c905/7335546/49383962570e/JAH3-9-e015139-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c905/7335546/760cc4427276/JAH3-9-e015139-g004.jpg

相似文献

1
Time to Shock the System: Moving Beyond the Current Paradigm for Primary Prevention Implantable Cardioverter-Defibrillator Use.是时候震撼这个系统了：超越目前用于一级预防植入式心脏复律除颤器使用的范式。
J Am Heart Assoc. 2020 Mar 3;9(5):e015139. doi: 10.1161/JAHA.119.015139. Epub 2020 Feb 24.
2
Subcutaneous implantable cardioverter defibrillator indication in prevention of sudden cardiac death in difficult clinical situations: A French expert position paper.皮下植入式心律转复除颤器在困难临床情况下预防心源性猝死的适应证：法国专家立场文件。
Arch Cardiovasc Dis. 2020 May;113(5):359-366. doi: 10.1016/j.acvd.2020.03.011. Epub 2020 Apr 22.
3
The evolution and revolution of the implantable cardioverter defibrillator.植入式心脏复律除颤器的演进与变革
Expert Rev Cardiovasc Ther. 2004 Jul;2(4):461-4. doi: 10.1586/14779072.2.4.461.
4
Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).大多数植入式心脏复律除颤器/心脏再同步治疗除颤器患者可行无诱导或有限电击测试：多中心ASSURE研究（心律失常单次电击除颤阈值测试与易损性上限：植入式心脏复律除颤器植入的风险降低评估）结果
Circulation. 2007 May 8;115(18):2382-9. doi: 10.1161/CIRCULATIONAHA.106.663112. Epub 2007 Apr 30.
5
End-of-life of implantable defibrillator: are we certain it should always be replaced?植入式心脏除颤器的使用寿命终结：我们确定它总是需要更换吗？
J Cardiovasc Med (Hagerstown). 2018 Feb;19 Suppl 1:e116-e119. doi: 10.2459/JCM.0000000000000554.
6
Progress in implantable cardioverter-defibrillator therapy: Advancement beyond technology alone.植入式心脏复律除颤器治疗的进展：超越技术本身的进步。
Trends Cardiovasc Med. 2015 Oct;25(7):612-3. doi: 10.1016/j.tcm.2015.02.009. Epub 2015 Feb 20.
7
Sudden cardiac death prevention: antiarrhythmic drugs and the implantable cardioverter-defibrillator.心脏性猝死的预防：抗心律失常药物与植入式心脏复律除颤器
J Interv Cardiol. 1995 Feb;8(1):9-15. doi: 10.1111/j.1540-8183.1995.tb00505.x.
8
[LifeVest - a novel treatment option prior to implantable cardioverter defibrillator].[生命背心——植入式心脏复律除颤器植入前的一种新型治疗选择]
Rev Med Suisse. 2017 Mar 1;13(552):500-504.
9
Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.延长器械寿命对植入式心脏转复除颤器治疗长期成本的影响：具有 15 年时间范围的建模研究。
Europace. 2013 Oct;15(10):1453-62. doi: 10.1093/europace/eut133. Epub 2013 May 21.
10
Mechanisms and management of inappropriate therapy in subcutaneous implantable cardioverter defibrillators.皮下植入式心律转复除颤器中不适当治疗的机制和管理。
J Cardiovasc Electrophysiol. 2019 Mar;30(3):402-409. doi: 10.1111/jce.13831. Epub 2019 Jan 6.

引用本文的文献

1
Multimodal AI to forecast arrhythmic death in hypertrophic cardiomyopathy.用于预测肥厚型心肌病心律失常性死亡的多模态人工智能
Nat Cardiovasc Res. 2025 Jul 2. doi: 10.1038/s44161-025-00679-1.
2
Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device's patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC.药物治疗和导管消融治疗持续血流左心室辅助装置患者心律失常：欧洲心律协会和欧洲心脏病学会心力衰竭协会的临床共识声明。
Europace. 2024 Nov 1;26(11). doi: 10.1093/europace/euae272.
3
Distinguishing Primary Prevention From Secondary Prevention Implantable Cardioverter Defibrillators Using Administrative Health and Cardiac Device Registry Data.

本文引用的文献

1
Joint Shock/Death Risk Prediction Model for Patients Considering Implantable Cardioverter-Defibrillators.考虑植入式心脏复律除颤器患者的关节休克/死亡风险预测模型
Circ Cardiovasc Qual Outcomes. 2019 Aug;12(8):e005675. doi: 10.1161/CIRCOUTCOMES.119.005675. Epub 2019 Aug 15.
2
Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial.用于预测植入式心脏复律除颤器获益的风险模型：来自丹麦试验的见解。
JACC Heart Fail. 2019 Aug;7(8):717-724. doi: 10.1016/j.jchf.2019.03.019. Epub 2019 Jul 10.
3
Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?
利用行政健康与心脏设备注册数据区分植入式心脏复律除颤器的一级预防和二级预防
CJC Open. 2024 Mar 7;6(7):876-883. doi: 10.1016/j.cjco.2024.02.003. eCollection 2024 Jul.
4
Implantable cardioverter defibrillators for primary prevention in cardiomyopathies.植入式心脏复律除颤器用于心肌病的一级预防。
Indian Heart J. 2024 Mar-Apr;76(2):118-122. doi: 10.1016/j.ihj.2024.03.005. Epub 2024 Mar 22.
5
QRS-T angle: is it a specific parameter associated with sudden cardiac death in type 2 diabetes? Results from the SURDIAGENE and the Mini-Finland prospective cohorts.QRS-T 夹角：它是否是与 2 型糖尿病患者心源性猝死相关的特异性参数？来自 SURDIAGENE 和 Mini-Finland 前瞻性队列研究的结果。
Diabetologia. 2024 Apr;67(4):641-649. doi: 10.1007/s00125-023-06074-4. Epub 2024 Jan 24.
6
Racial differences in setting of implantable cardioverter-defibrillator placement in older adults with heart failure and association with disparate post-implant outcomes.老年心力衰竭患者植入式心脏复律除颤器植入情况的种族差异及其与植入后不同结局的关联。
Front Cardiovasc Med. 2023 Sep 1;10:1197353. doi: 10.3389/fcvm.2023.1197353. eCollection 2023.
7
Patients' Perspectives Regarding Generator Exchanges of Implantable Cardioverter Defibrillators.患者对植入式心脏复律除颤器的发电机更换的看法。
Circ Cardiovasc Qual Outcomes. 2023 Aug;16(8):509-518. doi: 10.1161/CIRCOUTCOMES.122.009827. Epub 2023 Jul 26.
8
Polygenic Risk Score Predicts Sudden Death in Patients With Coronary Disease and Preserved Systolic Function.多基因风险评分可预测伴收缩功能保留的冠心病患者的猝死风险。
J Am Coll Cardiol. 2022 Aug 30;80(9):873-883. doi: 10.1016/j.jacc.2022.05.049.
9
Implantable Cardioverter Defibrillator in Primary and Secondary Prevention of SCD-What We Still Don't Know.植入式心脏复律除颤器在心脏性猝死一级和二级预防中的应用——我们仍未知晓的情况
J Cardiovasc Dev Dis. 2022 Apr 16;9(4):120. doi: 10.3390/jcdd9040120.
10
Mandates for Shared Decisions: Means to which Ends?共同决策的要求：手段服务于何种目的？
J Law Med Ethics. 2021;49(4):630-632. doi: 10.1017/jme.2021.86.
从心力衰竭上次住院到放置一级预防植入式心脏复律除颤器的时间与患者结局相关吗？
Circulation. 2018 Dec 11;138(24):2787-2797. doi: 10.1161/CIRCULATIONAHA.118.035627.
4
Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates.利用经验证的以患者为中心的风险评估来改进初级预防型植入式心脏除颤器治疗。
JACC Clin Electrophysiol. 2018 Aug;4(8):1089-1102. doi: 10.1016/j.jacep.2018.04.015. Epub 2018 Jun 27.
5
Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study.支持精准医学的真实世界证据：以临床基因组癌症数据为例。
Health Aff (Millwood). 2018 May;37(5):765-772. doi: 10.1377/hlthaff.2017.1579.
6
Sudden Cardiac Death: Lessons Learned from Cardiac Implantable Rhythm Devices.心脏性猝死：从心脏植入式节律装置中吸取的教训。
Card Electrophysiol Clin. 2017 Dec;9(4):749-759. doi: 10.1016/j.ccep.2017.08.005.
7
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.2017年美国心脏协会/美国心脏病学会/心律学会室性心律失常患者管理和心脏性猝死预防指南：执行摘要：美国心脏病学会/美国心脏协会临床实践指南工作组及心律学会的报告
J Am Coll Cardiol. 2018 Oct 2;72(14):1677-1749. doi: 10.1016/j.jacc.2017.10.053. Epub 2017 Oct 30.
8
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.2017年美国心脏协会/美国心脏病学会/心律学会室性心律失常患者管理和心脏性猝死预防指南：美国心脏病学会/美国心脏协会临床实践指南工作组和心律学会的报告
Circulation. 2018 Sep 25;138(13):e272-e391. doi: 10.1161/CIR.0000000000000549.
9
Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.非缺血性收缩性心力衰竭患者一级预防植入型心律转复除颤器的年龄和结局。
Circulation. 2017 Nov 7;136(19):1772-1780. doi: 10.1161/CIRCULATIONAHA.117.028829. Epub 2017 Sep 6.
10
Declining Risk of Sudden Death in Heart Failure.心力衰竭患者猝死风险降低。
N Engl J Med. 2017 Jul 6;377(1):41-51. doi: 10.1056/NEJMoa1609758.